175 related articles for article (PubMed ID: 38871488)
1. Polycythemia vera: past, present and future.
Patel AB; Masarova L; Mesa RA; Hobbs G; Pemmaraju N
Leuk Lymphoma; 2024 Jun; ():1-13. PubMed ID: 38871488
[TBL] [Abstract][Full Text] [Related]
2. SOHO State of the Art Update and Next Questions: Novel Therapies for Polycythemia Vera.
Masarova L; Chifotides HT
Clin Lymphoma Myeloma Leuk; 2024 Mar; 24(3):141-148. PubMed ID: 38135633
[TBL] [Abstract][Full Text] [Related]
3. Recent advances in prognostication and treatment of polycythemia vera.
Marcellino BK; Hoffman R
Fac Rev; 2021; 10():29. PubMed ID: 33817698
[TBL] [Abstract][Full Text] [Related]
4. Polycythemia Vera.
Spivak JL
Curr Treat Options Oncol; 2018 Mar; 19(2):12. PubMed ID: 29516275
[TBL] [Abstract][Full Text] [Related]
5. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
Gisslinger H; Klade C; Georgiev P; Krochmalczyk D; Gercheva-Kyuchukova L; Egyed M; Rossiev V; Dulicek P; Illes A; Pylypenko H; Sivcheva L; Mayer J; Yablokova V; Krejcy K; Grohmann-Izay B; Hasselbalch HC; Kralovics R; Kiladjian JJ;
Lancet Haematol; 2020 Mar; 7(3):e196-e208. PubMed ID: 32014125
[TBL] [Abstract][Full Text] [Related]
6. A pharmacokinetic evaluation of ropeginterferon alfa-2b in the treatment of polycythemia vera.
Illés Á; Pinczés LI; Egyed M
Expert Opin Drug Metab Toxicol; 2021 Jan; 17(1):3-7. PubMed ID: 33118413
[TBL] [Abstract][Full Text] [Related]
7. Polycythemia vera: scientific advances and current practice.
Tefferi A; Spivak JL
Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
[TBL] [Abstract][Full Text] [Related]
8. A phase II trial to assess the efficacy and safety of ropeginterferon α-2b in Chinese patients with polycythemia vera.
Jin J; Qin A; Zhang L; Shen W; Wang W; Zhang J; Li Y; Wu D; Xiao Z
Future Oncol; 2023 Apr; 19(11):753-761. PubMed ID: 37129584
[TBL] [Abstract][Full Text] [Related]
9. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
10. Ropeginterferon alfa-2 b for the therapy of polycythemia vera.
Červinek L
Vnitr Lek; 2020; 66(5):309-313. PubMed ID: 32942868
[TBL] [Abstract][Full Text] [Related]
11. Treatment options and pregnancy management for patients with PV and ET.
Edahiro Y
Int J Hematol; 2022 May; 115(5):659-671. PubMed ID: 35394259
[TBL] [Abstract][Full Text] [Related]
12. Enalaprilat and losartan decrease erythroid precursors frequency in cells from patients with polycythemia vera.
Bozza A; Bernardi M; Catanzaro D; Chieregato K; Merlo A; Astori G
Hematology; 2023 Dec; 28(1):2182056. PubMed ID: 36856520
[TBL] [Abstract][Full Text] [Related]
13. Chronic myeloproliferative disorders.
Spivak JL; Barosi G; Tognoni G; Barbui T; Finazzi G; Marchioli R; Marchetti M
Hematology Am Soc Hematol Educ Program; 2003; ():200-24. PubMed ID: 14633783
[TBL] [Abstract][Full Text] [Related]
14. Polycythemia vera: the current status of preclinical models and therapeutic targets.
Bartalucci N; Guglielmelli P; Vannucchi AM
Expert Opin Ther Targets; 2020 Jul; 24(7):615-628. PubMed ID: 32366208
[TBL] [Abstract][Full Text] [Related]
15. How We Identify and Manage Patients with Inadequately Controlled Polycythemia Vera.
Reiter A; Harrison C
Curr Hematol Malig Rep; 2016 Oct; 11(5):356-67. PubMed ID: 26894383
[TBL] [Abstract][Full Text] [Related]
16. Polycythemia vera and essential thrombocythemia: 2019 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2019 Jan; 94(1):133-143. PubMed ID: 30281843
[TBL] [Abstract][Full Text] [Related]
17. Contemporary Challenges in Polycythemia Vera Management From the Perspective of Patients and Physicians.
Kuykendall AT; Fine JT; Kremyanskaya M
Clin Lymphoma Myeloma Leuk; 2024 Apr; ():. PubMed ID: 38749802
[TBL] [Abstract][Full Text] [Related]
18. Current and future treatment options for polycythemia vera.
Griesshammer M; Gisslinger H; Mesa R
Ann Hematol; 2015 Jun; 94(6):901-10. PubMed ID: 25832853
[TBL] [Abstract][Full Text] [Related]
19. Evolving Therapeutic Options for Polycythemia Vera: Perspectives of the Canadian Myeloproliferative Neoplasms Group.
Sirhan S; Busque L; Foltz L; Grewal K; Hamm C; Laferriere N; Laneuville P; Leber B; Liew E; Olney HJ; Prchal J; Porwit A; Gupta V
Clin Lymphoma Myeloma Leuk; 2015 Dec; 15(12):715-27. PubMed ID: 26433906
[TBL] [Abstract][Full Text] [Related]
20. Evaluating ropeginterferon alfa-2b for the treatment of adults with polycythemia vera.
Krecak I; Skelin M; Verstovsek S
Expert Rev Hematol; 2023 May; 16(5):305-316. PubMed ID: 37002907
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
